Algorithms for the medical treatment of attention-deficit/hyperactivity disorder with specific co-morbidities;Medikamentöse behandlungsalgorithmen bei aufmerksamkeitsdefizit- hyperaktivitätsstörungen unter berücksichtigung spezifischer komorbiditäten

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 38, Issue 1, 2010, Pages 7-20

  Frölich, Jan ^a,b   Lehmkuhl, Gerd ^a   Döpfner, Manfred ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE   (Germany)

Author keywords

ADHD; Aggressive behavior; Anxiety disorders; Atypical neuroleptics; Depression; Psychostimulants; Serotonin reuptake inhibitors; Tic disorders

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BODY WEIGHT; BRAIN METABOLISM; CHILD; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; FEAR; GERMANY; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; PATIENT ASSESSMENT; REVIEW; SIDE EFFECT;

EID: 74849124596     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.a000002     Document Type: Review

References (112)

1. Abikoff, H., McCough, J., Vitiello, B., McCracken, J., Davies, M., Walkup, J. et al. (2005). Sequential pharmacotherapy for children with comorbid attention deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 418-427.
2. Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W. et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941-1949.
3. Aman, M. G., Arnold, L. E., McDougle, C. J., Vitello, B., Scalhill, L., Davies, M. et al. (2005). Acute and long-term safety and tolerability of children with autism. Journal of Child and Adolescent Psychopharmacology, 15, 869-884.
4. Aman, M. G., Armstrong, S., Buican, B. & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.
5. Aman, M. G., Binder, C. & Turgay, A. (2004). Risperidone Effects in the Presence/Absence of Psychostimulant Medicine in Children with ADHD, Other Disruptive Behavior Disorders, and Subaverage IQ. Journal of Child and Adolescent Psychopharmacology, 14, 243-254.
6. Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Ascherson, P., Buitelaar, J. et al. (2006). Long-acting medications for the hyperkinetic disorders: A systematic review and European guideline. European Child and Adolescent Psychiatry, 15, 476-495.
7. Bangs, M. E., Emslie, G. J., Spencer T. J., Ramsey, J. L., Detke, H. C., Allen, A. J. et al. (2005). A study of atomoxetine in adolescents with ADHD and comorbid depression. Paper presented at 45 th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), June 6-9, Boca Raton, Fl.
8. Barrickman, L., Noyes, R., Kuperman, S., Schumacher, E. & Verda, M. (1991). Treatment of ADHD with fluoxetine: A preliminary trial. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 762-767.
9. Benjamin, E. & Salek, S. (2005). Stimulant-atypical antipsychotic interaction and acute dystonia. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 510-512.
10. Biederman, J., Lopez, F. A., Boellner, S. W. & Chandler. M. C. (2002). A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics, 110(2Pt 1), 258-266.
11. Birmaher, B., Brent, D., & AACAP work group on quality issues. (2007). Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1503-1526.
12. Birmaher, B., Yelovich, K. & Renaud, J. (1998). Pharmacologic treatment for children and adolescents with anxiety disorders. Pediatric Clinics of North America, 45, 1187-1204.
13. Black, B. & Uhde, T. W. (1994). Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 1000-1006.
14. Bruggeman, R., van der Linden, C., Buitelaar, J. K., Gericke G. S., Hawkridge, S. M. & Temlett, J. A. (2001). Risperidone vas pimozide in Tourettes' disorder: A comparative double-blind parallel-group study. Journal of Clinical Psychiatry, 62, 50-56.
15. Bubl, E., Perlov, E., & Tebartz Van Elst, L. (2006). Aripiprazole in patients with Tourette syndrome. World Journal of Biological Psychiatry, 7, 123-125.
16. Buitelaar, J. K. (2000). Open-label treatment with risperidone of 26 psychiatrically hospitalized children and adolescents with mixed diagnoses and aggressive behavior. Journal of Child and Adolescent Psychopharmacology, 10, 19-26.
17. Campbell, M., Adams, P. B., Small, A. M., Kafantaris, V., Silva, R. R., Shell, J. et al. (1995). Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 589-596.
18. Castellanos, F. X., Giedd, J. N., Elia, J., Marsh, W. L., Ritchie, G. F., Hamberger, S. D. et al. (1997). Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 589-596.
19. Cohen, D. (2007). Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? Psychotherapie und Psychosomatik 76(1), 5-14.
20. Conners, C. K., Casat, C., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A. et al. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of Child and Adolescent Psychopharmacology, 35, 1314-1321.
21. Connor, D., Glatt, S., Lopez, I., Jackson, D. & Melloni, R. (2002). Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 253-261.
22. Conolly, S. D., & Bernstein, G. A. (2007). Practice Parameter for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 267-283.
23. Correia Filho A. G., Bodanese, R., Silva, T. L., Alares, J. P., Aman, M. & Rohde, L. A. (2005). Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 748-55.
24. Donovan, S. J., Stewart, J. W., Nunez, E. V., Quitkin, F. M., Parides, M., Daniel, W. et al. (2000). Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. American Journal of Psychiatry, 157, 818-820.
25. Döpfner, M., Lehmkuhl, G., Schepker, R. & Frölich, J. (2007). Hyperkinetische Störungen (F90.0). Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Bundesarbeitsgemeinschaft Klinikärzte der leitenden Klinikärzte für Kinder- und Jugendpsychiatrie und Psychotherapie & Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (S. 239-254). Köln: Deutscher Ärzte Verlag.
26. DuPaul, G. J., Power, T. J., Anastopoulos, A. D. & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford.
27. Efron, D., Jarman, F. & Barker, M. (1997). Methylphenidat versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics, 100, E6.
28. Eggers, C., Rothenberger, A. & Berghaus, U. (1988). Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. European Archive Psychiatry Neurological Science, 237, 223-239.
29. Emslie, G. J., Findling, R. L., Yeung, P. P., Kunz, N. R. & Li, Y. (2007). Venlafacine ER for the treatment of pediatric subjects with depression: Results of two placebo-controlled trials. Journal of Child and Adolescent Psychopharmacology, 46, 479-488.
30. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E. et al. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomised clinical trial. Journal of Child and Adolescent Psychopharmacology, 41, 1205-1215.
31. Emslie, G. J., Rush, A. J. & Weinsberg, W. A. (1997). A double-blind, randomised, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archive Genetic Psychiatry, 54, 1031-1037.
32. Emslie, G. J., Wagner, K. D., Kutcher, S., Krulewicz, S., Fong, R., Carpenter, D. et al. (2006). Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 709-719.
33. Fegert, J. M. & Herpertz-Dahlmann, B. (2004). Administration of selective serotonin reuptake inhibitors (SSRI) for depression in children and adolescents. Der Nervenarzt, 75, 908-910.
34. Fegert, J. M. & Herpertz-Dahlmann, B. (2005). Serotonin reuptake inhibitors in children. Warnings on the administration, results analysis, and recommendations. Der Nervenarzt, 76, 1330-1339.
35. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E. & Blumer, J. L. (2000). A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 509-516.
36. Findling, R. L., Newcorn, J. H., Malone, R. P., Waheed, A., Prince, J. B. & Kratochvil, C. J. (2007). Pharmacotherapy of aggression in a 9-year-old with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 653-658.
37. Freeman, R. D., Fast, D. K., Burd, L., Kerbeshian, J., Robertson, M. M. & Sandor, P. (2000). An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. Developmental Medicine and Child Neurology, 42, 436-447.
38. Gadow, K. D., Nolan, E. E., Sverd, J., Sprafkin, J. & Schwartz, J. (2002). Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology, 22, 267-274.
39. Gadow, K. D., Sverd, J., Sprafkin, J., Nolan, E. E. & Ezor, S. N. (1995). Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Archives of Genetic Psychiatry, 52, 444-455.
40. Gadow, K. S., Sverd, J., Sprafkin, J., Nolan, E. E. & Grossman, S. (1999). Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Archives of Genetic Psychiatry, 56, 330-336.
41. Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V. et al. (2007). Atomoxetine Treatment for Pediatric Patients With Attention-Deficit/Hyperactivity Disorder With Comorbid Anxiety Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1119-1127
42. . Gilbert, D. L., Batterson, J. R., Sethuraman, G. & Sallee, F. R. (2004). Tic reduction with risperidone versus pimozide in a randomised, double-blind, crossover trail. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 206-214.
43. Günther, T., Herpertz-Dahlmann, B., Jolles, J. & Konrad, K. (2006). The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behaviour disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 16, 725-35.
44. Hazell, P. L. & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 886-894.
45. Hegerl, U. (2007). Antidepressants and suicidality: Risk-benefit analysis. Der Nervenarzt, 78, 7-14.
46. Holtmann, M., Bölte, S. & Poustka, F. (2006). Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors. Review and meta-analysis of the available randomised, placebo controlled trials. Der Nervenarzt, 77, 1332-1337.
47. Hughes, C. W., Emslie, G. J., Crismon, M. L., Posner, K., Birmaher, B., Ryan, N. et al. (2007). The Texas Children's Medication Algorithm Project: Update from texas consensus conference panel on medication treatment of childhood major depressive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 667-686.
48. Ipser, J. & Stein, D. J. (2007). Systematic review of pharmacotherapy of disruptive behavior in children and adolescents. Psychopharmacology, 191, 127-140.
49. Jensen, P. S., Hinshaw, S. P., Kraemer, H. C., Lenora, N., Newcorn, J. H., Abikoff, H. B. et al. (2001). ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 147-158.
50. Jensen, P. S., Youngstrom, E. A., Steiner, H., Findling, R. L., Meyer, R. E., Malone, R. P. et al. (2007). Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 309-322.
51. Jick, H., Kaye, J. A. & Jick, S. S. (2004). Antidepressants and the risk of suicidal behaviors. JAMA, 292, 338-343.
52. Klein, R. G., Abikoff, H., Klass, E., Ganeles, D., Seese, L. M. & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder. Archives of Genetic Psychiatry, 54, 1073-1080.
53. Kratochvil, C. J., Vitiello, B., Brent, D., Bostic, J. Q. & Naylor, M. W. (2006). Selecting an antidepressant for the treatment of pediatric depression. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 371-373.
54. Labellarte, M. J., Ginsburg, G. S., Walkup, J. T. & Riddle, M. A. (1999). The treatment of anxiety disorders in child and adolescents. Biological Psychiatry, 46, 1567-1578.
55. Leon, A. C., Marzuk, P. M., Tardiff, K., Bucciarelli, A., Piper, T. M. & Galea, S. (2006). Antidepressants and youth suicide in New York City, 1999-2002. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1054-1058.
56. Manassis, K. (2000). Childhood anxiety disorders: Lessons from the literature. Canadian Journal of Psychiatry, 45, 724-730.
57. Masi, G., Toni, C., Mucci, M., Millepiedi, S., Mata, B. & Perugi, G. (2001). Paroxetine in child and adolescent outpatients with panic disorder. Journal of Child and Adolescent Psychopharmacology, 11, 151-157.
58. Michelsen, D., Allen, A. J., Busner, K., Casat, C., Dunn, D., Kratochvil, C. et al. (2002). Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
59. Müller-Vahl, K. R. (2002). The treatment of Tourette's syndrome: Current opinions. Expert Opinion Pharmacotherapy, 3, 899-914.
60. Müller-Vahl, K. R., Geomelas, M., & Makowski, L. (2004). Clinical Symptoms in Tourette syndrome: A prospective study in 480 patients. Poster abstracts. 4th International Scientific Symposium on Tourette-Syndrome, Cleveland, Ohio.
61. Mukaddes, N. M. & Abali, O. (2003). Quetiapine treatment of children and adolescents with Tourette's disorder. Journal of Child and Adolescent Psychopharmacology, 13, 295-299.
62. Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R. & Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 240-248.
63. Olfson, M., Blanco, C., Liu, L., Moreno, C. & Laje, G. (2006). National trends in outpatient treatment of children and adolescents with antipsychotic drugs. Archives of Genetic Psychiatry, 63, 679-685.
64. Onofrrij, M., Paci, C. & D'Andeamatteo, T. L. (2000). Olanzapine in severe Golles de la Tourette syndrome: 52 week double - blind double-blind cross-over study vs. low-dose pimozide. Journal of Neurology, 247, 443-446,
65. Pandina, G. J., Aman, M. G. & Findling, R. L. (2006). Risperidone in the management of disruptive behaviour disorders. Journal of Child and Adolescent Psychopharmacology, 16, 379-392.
66. Pappadopulos, E., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A. et al. (2003). Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II. Recommendations for clinicians. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 145-161.
67. Plisaka, S.,& AACAP work group on quality issues. (2007). Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-deficit/hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 894-921.
68. Pliszka, S. R. (1998). Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: An overview. Journal of Clinical Psychiatry, 59, 50-58.
69. Pliszka, S. R. (2003). Psychiatric comorbidities in children with attention deficit hyperactivity disorder: Implications for management. Paediatric Drugs, 5, 741-750.
70. Pliszka, S. R., Crismon, M. L., Hughes, C. W., Conners, C. K., Emslie, G. J., Jensen, P. S. et al. (2006). The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 642-647.
71. Postolache, T. T., Rosenthal, R. N., Hellerstein, D. J., Aromin, R., Kelton, G. M., Muran, J. C. et al. (1999). Early augmentation of sertraline with methylphenidate. Journal of Clinical Psychiatry, 60, 123-124.
72. Prasad, S. et al. (2006). A randomised, controlled, open-label study of the broader efficacy of atomoxetine hydrochloride in comparison to standard current therapy in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in UK children and adolescents. Posterpräsentation auf der 25. Konferenz des Collegium Internationale Neuro-Psychopharmacologicum Psychiatry (CINP), 9.-13. Juli 2006, Chicago, USA.
73. Ralston, S. J., Lorenzo, M. J. & ADORE study group. (2004). ADORE - Attention-Deficit Hyperactivity Disorder Observational Research in Europe. European Child and Adolescent Psychiatry, 13, 136-142.
74. Regeur, L., Pakkenberg, B., Fog, R. & Pakkenberg, H. (1986). Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. Journal of Neurology and Neurosurgery Psychiatry, 49, 791-795.
75. Renaud, J., Birmaher, B., Wassick, S. C. & Bridge, J. (1999). Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: A pilot study. Journal of Child and Adolescent Psychopharmacology, 9, 73-83.
76. Research Units on Pediatric Psychopharmacology Anxiety Study Group (RUPP). (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine, 344, 1279-1285.
77. Research Units on Pediatric Psychopharmacology Anxiety Study Group (RUPP). (2003). Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. Journal of American Academy of Child and Adolescent Psychiatry, 42, 13-21.
78. Robertson, M. M. & Stern, J. S. (2000). Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. European Child & Adolescent Psychiatry, 9, 160-175.
79. Roessner, V., Banaschewski, T. & Rothenberger, A. (2004). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 32, 245-263.
80. Rothenberger, A. & Banaschewski, T. (2003). Ticstörungen. Arbeitsgemeinschaft Medizinischer Fachgesellschaften (AWMF, Ed.). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (S. 311-317). Köln: Deutscher Ärzte Verlag.
81. Rynn, M., Kunz, N., Lamm, L., Nicolacopoulos, E. & Jenkins, L. (2002). Venlafaxine XR for treatment of GAD in children and adolescents. Presented at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 22-27.
82. Sabuncuoglu, O. (2007). Risperidone-to-methylphenidate switch reaction in children: Three cases. Journal of Psychopharmacology, 21, 216-219.
83. Sallee, F. R., Kurlan, R., Goetz, C. G., Singer, H., Scahill, L., Law, G. et al. (2000). Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 292-299.
84. Sandor, P., Musisi, S., Moldofsky, H. & Lang, A. (1990). Tourette syndrome: A follow-up study. Journal of Clinical Psychopharmacology, 10, 197-199.
85. Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J. et al. (2006). Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 3, 192-206.
86. Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, K. & Peterson, B. S. (2003). A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 60, 1130-1135.
87. Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A. et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). I: A review. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 132-144.
88. Silva, R. R., Munoz, D. M. & Alpert, M. (1996). Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 352-358.
89. Sinzig, J., Döpfner, M., Lehmkuhl, G. & German Methylphenidate Study Group. (2007). Long-acting methylphenidate has an effect on aggressive behavior in children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 17, 421-432.
90. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A. et al. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026-1036.
91. Spencer, T., Biederman, J., Coffey, B., Geller, D., Crawford, M., Bearman, S. K. et al. (2002). A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of Genetic Psychiatry, 59, 649-656.
92. Spencer, T. J., Abikoff, H. B., Connor D. F., Biedermann, J., Plisaka, S. R., Boellner, S. et al. (2006). Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder in schoolaged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clinical Therapy, 28, 402-418.
93. Stoll, A. L., Pillay, S. S., Diamond, L., Workum, S. B. & Cole, J. O. (1996). Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. Journal of Clinical Psychiatry, 57, 72-76.
94. Sukhodolsky, D., Scahill, L., Zhang, H., Peterson, B. S., Kind, R. A., Lombroso, P. J. et al. (2003). Disruptive behaviour in children with Tourette's Syndrome: Association of ADHD comorbidity, tic severity, and functional impairment. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 98-105.
95. TADS Team. (2004). The Treatment for Adolescents with Depression Study (TADS): Short-term effectiveness and safety outcomes. JAMA, 292, 807-820.
96. Tannock, R. (1994). Attention deficit disorders with anxiety disorders. In T.E. Brown (Ed.), Subtypes of Attention Deficit Disorders in children, adolescents and adults. New York: American Psychiatric Press.
97. Tannock, R., Ickowicz, A. & Schachar, R. (1995). Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 886-896.
98. Taylor, E., Döpfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J. et al. (2004). European clinical guidelines for hyperkinetic disorder - first upgrade. European Child and Adolescent Psychiatry, 13, 7-30.
99. Taylor, E., Schachar, R., Thorley, G., Wieselberg, H. M., Everitt, B. & Rutter, M. (1987). Which boys respond to stimulant medication? A controlled trial of MPH in boys with disruptive behaviour. Psychological Medicine, 17, 121-143.
100. The MTA Cooperative Group. (1999). A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archive Genetic Psychiatry, 56, 1073-1086.
101. Tourette Syndrome Study Group. (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58, 527-536.
102. Treatment for Adolescents With Depression Study (TADS) Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomised control trial. JAMA, 292, 807-820.
103. Urman, R., Ickowicz, A., Fulford, P. & Tannock, R. (1995). An exaggerated cardiovascular response to methylphenidate in ADHD children with anxiety. Journal of Child and Adolescent Psychopharmacology, 5, 29-37.
104. Van Bellinghen, M. & De Troch, C. (2001). Risperidone in the treatment of behaviour disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5-13.
105. Varley, C. K. (2001). Sudden death related to selected tricyclic antidepressants in children: Epidemiology, mechanisms and clinical implications. Paediatric Drugs, 3, 613-627.
106. Wagner, K. D., Ambrosini, P. J., Rynn, M., Wohlberg, C., Gang, R., Greenbaum, N. S. et al. (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA, 290, 1033-1041.
107. Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J. et al.(2004). A multicenter, randomized, double-blind placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Archives of General Psychiatry, 61, 1153-1162
108. Wagner, K. D., Jona, J., Findling, R. L., Ventura, D. & Saikali, K. (2006). A randomised, placebo-controlled trial of escitalopram in the treatment of pediatric depression. Journal for American Psychiatry, 45, 280-288.
109. Wagner, K. D., Robb, A. S., Findling, R. L., Jin, J., Gutierrez, M. M. & Heydorn, W. E. (2004). A randomised, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Journal for American Psychiatry, 161, 1079-1083.
110. Walsh, M. T. & Dinan, T. G. (2001). Serotonin-Reuptake-Inhibitors and violence: A review of the available evidence. Acta Psychiatrica Scandinavia, 104, 84-91
111. Wilhelm, S., Deckersbach, T., Coffey, B. J., Bohne, A., Peterson, A. L. & Baer, L. (2003). Habit reversal versus supportive psychotherapy for Tourette's disorder: A randomized controlled trial. American Journal of Psychiatry, 160, 1171-1175.
112. Woods, D. W., Twohig, M. P., Flessner, C. A. & Roloff, T. J. (2003). Treatment of vocal tics in children with Tourette syndrome: Investigating the efficacy of habit reversal. Journal of Applied Behavioral Analysis, 36, 109-112